These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29768717)

  • 1. Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.
    Muller AE; Punt N; Engelhardt M; Schmitt-Hoffmann AH; Mouton JW
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):781-787. PubMed ID: 29768717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.
    Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
    Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K
    Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J; Das S; Zhou D; Al-Huniti N
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):682-694. PubMed ID: 31044546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftobiprole: pharmacokinetics and PK/PD profile.
    Azanza Perea JR; Sádaba Díaz de Rada B
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):11-16. PubMed ID: 31364336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
    Torres A; Mouton JW; Pea F
    Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
    Rubino CM; Cammarata AP; Smits A; Schröpf S; Polak M; Litherland K; Hamed K
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0120621. PubMed ID: 34398669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
    Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
    Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
    Muller AE; Schmitt-Hoffmann AH; Punt N; Mouton JW
    Antimicrob Agents Chemother; 2013 May; 57(5):2047-53. PubMed ID: 23403430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
    Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
    J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
    Murthy B; Schmitt-Hoffmann A
    Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
    Barbour A; Schmidt S; Sabarinath SN; Grant M; Seubert C; Skee D; Murthy B; Derendorf H
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2773-6. PubMed ID: 19364847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole quantification in human serum by HPLC-UV to implement routine TDM in clinical practice.
    Boccardi D; Marini V; Baiardi G; Cameran Caviglia M; Sacco F; Piras F; Del Puente F; Boni S; Pontali E; Mattioli F
    Clin Chim Acta; 2024 Jul; 561():119806. PubMed ID: 38852792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefozopran by single and multiple intravenous infusions in healthy Chinese volunteers.
    Wu GL; Shentu JZ; Zhou HL; Zhu MX; Hu XJ; Liu J; Wu LH
    Drugs R D; 2015 Mar; 15(1):63-70. PubMed ID: 25644122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
    Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
    J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
    Rodvold KA; Nicolau DP; Lodise TP; Khashab M; Noel GJ; Kahn JB; Gotfried M; Murray SA; Nicholson S; Laohavaleeson S; Tessier PR; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3294-301. PubMed ID: 19451287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.